S-Biomedic Revenue and Competitors
Estimated Revenue & Valuation
- S-Biomedic's estimated annual revenue is currently $4.3M per year.
- S-Biomedic's estimated revenue per employee is $155,000
Employee Data
- S-Biomedic has 28 Employees.
- S-Biomedic grew their employee count by 8% last year.
S-Biomedic's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | Co-founder, CEO | Reveal Email/Phone |
3 | Director Product Development & clinical research | Reveal Email/Phone |
4 | Chief Commercial Officer | Reveal Email/Phone |
S-Biomedic Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is S-Biomedic?
S-Biomedic has developed a direct skin microbiome manipulation technology which allows to transplant beneficial bacteria on the skin. We pack skin microbiome transplantation into cosmetics.
keywords:N/AN/A
Total Funding
28
Number of Employees
$4.3M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
S-Biomedic News
2022-04-17 - Biotech Tries Manipulating the Skin Microbiome
Belgian biotechnology company S-Biomedic has characterized some of these changes in the microbiome of the face, and the Cutibacterium...
2022-04-06 - The live biotherapeutic products and microbiome ...
Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic); Nikole Kimes (Founder and Chief Executive Officer, Siolta Therapeutics)...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 30 | 100% | N/A |
#2 | $5M | 30 | 50% | N/A |
#3 | N/A | 31 | 29% | N/A |
#4 | $9.6M | 34 | -6% | N/A |
#5 | N/A | 36 | 24% | N/A |